RARECast

Podcast autorstwa RARECast - Czwartki

Czwartki

Kategorie:

516 Odcinki

  1. A Gene Therapy Company Born from a Father’s Efforts to Save his Daughter

    Opublikowany: 7.11.2024
  2. Lowering Barriers to Clinical Trial Participation with Do-It-Yourself Blood Sample Collection

    Opublikowany: 31.10.2024
  3. Scaling N-of-1 Therapies to Viability

    Opublikowany: 24.10.2024
  4. Building Gene Therapies that Address Gain and Loss of Function Simultaneously

    Opublikowany: 17.10.2024
  5. How One Woman Climbed from Patient to Advocate

    Opublikowany: 10.10.2024
  6. Shortening the Diagnostic Odyssey

    Opublikowany: 3.10.2024
  7. Making Exomes More Revealing

    Opublikowany: 26.09.2024
  8. How One Patient Organization Catalyzed Drug Development

    Opublikowany: 19.09.2024
  9. Enabling On-Demand Therapies

    Opublikowany: 16.09.2024
  10. After Driving an N-of-1 Therapy for Her Son, an Advocate Turns to Helping Others

    Opublikowany: 5.09.2024
  11. Putting Rare Disease Organization in the Business of Drug Development

    Opublikowany: 29.08.2024
  12. Understanding the Many Questions Gene Therapies Raise

    Opublikowany: 22.08.2024
  13. A Test to Identify People Likely to Develop ALS

    Opublikowany: 15.08.2024
  14. How an Ultra-Rare Disease Patient Foundation Advanced a Gene Therapy

    Opublikowany: 8.08.2024
  15. Making the $10 Genome a Reality

    Opublikowany: 1.08.2024
  16. A No-Nonsense Effort to Develop a Therapy that Works Across Genetic Diseases

    Opublikowany: 25.07.2024
  17. Mapping a Perilous Journey with Humor

    Opublikowany: 18.07.2024
  18. Restoring Vision in Inherited Retinal Disease

    Opublikowany: 11.07.2024
  19. Bringing Genome Sequencing to Rural Populations

    Opublikowany: 4.07.2024
  20. Addressing a Blind Spot in Treatments for the Cornea

    Opublikowany: 27.06.2024

1 / 26

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.

Visit the podcast's native language site